Treatment was associated with CD4+ T-cell elevation, which has been reported elsewhere as a hallmark of early response to anti-PD-L1 and anti-CTLA-4 combination therapy in patients with HNSCC.23 Here, CTLA4 is linked to head and neck squamous cell carcinoma.